Biotech Daily

Thursday October 29, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: MESOBLAST UP 23%; CURVEBEAM DOWN 10.5%**

*** MESOBLAST Q1 RECEIPTS UP 243% TO $50m**

*** SALUDA Q1 RECEIPTS $33m**

*** DIMERIX $14m Q1 RECEIPTS FROM EVEREST LICENCE**

*** VICTORIA $2m FOR mRNA CANCER TREATMENTS**

*** AROVELLA: 'ALA-105 CLEARS GASTRIC CANCER, IN 5 OF 7 MICE'**

*** ATOMO, INNOVATION SCIENTIFIC DEVELOP HIV ASSAY**

*** CERETAS ENROLS 1st PHASE II ULTRASOUND ALZHEIMER'S PATIENT**

*** TETRATHERIX: 'TENEGEOS HEALS TENDONS, IN RATS'**

*** CONTROL BIONICS UNMARKETABLE PARCEL FACILITY**

*** PARADIGM: COURT DELAYS CREDITOR MEETING**

*** ANTERIS 2.3m DIRECTORS STOCK, 1.6m OPTIONS, $1.6m OPTIONS AGM**

*** NOXOPHARM TAKES 'CAPITAL RAISING' HALT TO SUSPENSION**

*** NEURIZON REQUESTS 'CAPITAL RAISING' TRADING HALT**

*** POGGINSWOOD TAKES 5% OF RENERVE**

MARKET REPORT

The Australian stock market was up 0.50 percent on Thursday October 29, 2026, with the ASX200 up 44.5 points to 8,891.8 points. Twenty-two of the Biotech Daily Top 40 were up, 13 fell, four traded unchanged and one was untraded. All four Big Caps were up.

Mesoblast was best, up 44 cents or 23.4 percent to $2.32, with 17.4 million shares traded. Impedimed improved 12.5 percent; Botanix and Proteomics climbed more than nine percent; Imugene was up 8.6 percent; Actinogen and Amplia were up more than seven percent; Clarity and Neuren rose more than six percent; Prescient and Syntara were up more than five percent; Avita, Cyclopharm and Dimerix climbed more than four percent; Artrya and Telix were up three percent or more; Clinuvel, Compumedics and Racura rose more than two percent; Aroa, Cochlear, Lumos and Polynovo were up more than one percent; with CSL, Pro Medicus and Resmed up by less than one percent.

Curvebeam led the falls, down 0.2 cents or 10.5 percent to 1.7 cents, with 9.95 million shares traded. EBR and Micro-X lost more than seven percent; Atomo and Starpharma were down more than six percent; 4D Medical and Immutep fell more than four percent; Imricor, Optiscan and Saluda shed three percent or more; Resonance was down 1.3 percent; with Medical Developments and Orthocell down by less than one percent.

MESOBLAST

Mesoblast says customer receipts for the three months to September 30, 2026 rose 243.4 percent to $US35,433,000 ($A50,228,000), compared to the prior corresponding period.
Mesoblast said net revenue from sales of its Ryoncil, or remestemcel-L, mesenchymal stem cells for graft-versus-host disease was up 44 percent to $US28 million, with September including “the highest number of new patient starts per month” following an expected seasonality from summer recess-related treatment scheduling.
Mesoblast chief executive Prof Silviu Itescu said the three-month results showed “continued momentum for Ryoncil sales”.
“Importantly, we have shown substantial improvement in our net operating cash spend while continuing to advance our strategic objectives for rexlemestrocel-L in chronic pain and cardiovascular diseases,” Prof Itescu said.
The company said that it had a cash burn of $US2,128,000 for the three months to September 30, 2026.
Mesoblast said that it had cash and cash equivalents of $US98,545,000, at September 30, 2026, compared to $US144,719,000 at September 30, 2025.
Mesoblast was up 44 cents or 23.4 percent to $2.32 with 17.4 million shares traded.

SALUDA MEDICAL

Saluda says receipts from customers for the three months to September 30, 2026 were $US23,508,000 ($A33,298,000).
Last year, the Sydney, Delaware and Bloomington, Minnesota-based Saluda said it raised $US150 million in an initial public offer to commercialize its spinal cord stimulation to reduce pain (BD: Nov 13, 2025).
Today, the company said revenue from sales of its closed-loop, dose-controlled spinal cord stimulation therapy was up 26 percent to $US23.1 million for the three months to September 30, 2026, compared to the previous corresponding period.
Saluda said that US revenue was up 34 percent to $US17.4 million, with patient numbers “exceeding revenue growth, primarily reflecting customers’ use of inventory purchased in prior quarters and account mix, including increased activity in higher-volume [ambulatory surgical centre] with volume-based pricing”.
The company said it had a cash burn of $US42,672,000 for the three months, with cash and cash equivalents of $US73,605,000 at September 30, 2026, leaving it with 2.3 quarters of available funding.
Saluda fell one cent or 3.8 percent to 25.5 cents.

DIMERIX

Dimerix says three-month receipts of $14,146,000 to September 30, 2026 came from an up-front payment from Everest Medicines under a licence agreement for DMX-200.
In June, Dimerix said it had an up-to $481 million licence agreement for its DMX-200 for focal segmental glomerulo-sclerosis (FSGS) with Hong Kong’s Everest Medicines; and later, and said it received a $US10 million ($A14.1 million) up-front payment under the licence agreement (BD: Jun 16, Aug 20, 2026).
Today, the company said it had a $9,048,000 positive cash flow for the three months, with cash and cash equivalents of $34,843,000 at September 30, 2026 compared to $49,238,000 at September 30, 2025.
Dimerix was up one cent or 4.9 percent to 21.5 cents.

VICTORIA GOVERNMENT, UNIVERSITY OF MELBOURNE
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Victoria Government says it will provide $1.98 million to two research teams for messenger (m)RNA technologies for solid cancers.

A media release form the Minister for Economic Development and Medical Research Anthony Carbines said the funds were provided through the mRNA Victoria Pipeline grant program, with the Walter and Eliza Hall Institute (WEHI) to receive $1 million and the University of Melbourne to receive $980,000.

The Victoria Government said the WEHI research would "support the development of potential mRNA treatments for aggressive brain cancers in children and adults".

The Government said the University of Melbourne project would investigate how mRNA technology could help immune cells better target solid cancers making chimeric antigen receptor (CAR) T-cell therapies more effective.

The State Government said the mRNA Victoria Pipeline grant program helped researchers progress treatments from pre-clinical research towards phase I clinical trials; and it had invested $36 million in 67 RNA research projects since 2021.

Mr Carbines said the Government was "backing Victoria's world-class researchers to develop new cancer treatments and offer hope to patients here and around the world".

"By advancing cutting-edge research towards clinical trials, we're keeping Victoria at the forefront of medical innovation," Mr Carbines said.

The Government said that its support of mRNA research was "delivering promising results strengthening Victoria's pipeline of new vaccines and therapies ,,, [including] a world-first lupus clinical trial, new treatments for bone marrow failure syndrome, with malaria and hepatitis C … also progressing towards clinical trials".

The Victoria Government said the state was "Australia's leading destination for clinical trials" with about 30 percent of all clinical trial sites.

AROVELLA THERAPEUTICS

Arovella says its ALA-105 CAR-INKT cells led to no sign of gastric cancer tumor in five of seven mice treated after 60 days, compared to no survival in control.

Arovella said that in a smaller sub-group of mice treated with interleukin-12-armored ALA-105 chimeric antigen receptor (CAR) invariant natural killer T (INKT) cells, tumors were eliminated in all treated animals, and all animals survived the 60-day study.

The company said in addition to the strong tumor control shown the study "also confirmed that INKT cells lacking a specific tumor-targeting CAR possess an inherent ability to recognize and attack tumor cells and were able to delay gastric tumor growth compared with untreated controls".

Arovella said the findings built on its "previously reported in-vitro data and provide further evidence that CAR-INKT cells may offer a highly effective approach for treating [claudin-18 isoform 2]-positive solid tumors, including gastric cancer".

The company said it would progress manufacturing development and seek US Food and Drug Administration feedback on the proposed clinical pathway.

Arovella chair David Williams said the data showed "the versatility and power of our INKT cell platform".

"The ability to achieve complete tumor clearance and survival in this challenging gastric cancer model reinforces the significant potential of our technology to address unmet needs in solid tumors," Mr Williams said. "The results are so compelling that we have resolved to speed up a formal approach to the FDA."

Arovella was unchanged at 5.1 cents.

ATOMO DIAGNOSTICS

Atomo says it will develop a fourth generation HIV rapid test using its Galileo cassette with Sydney's Innovation Scientific.

Atomo said that it had completed feasibility studies, Innovation Scientific would conduct additional development, analytical and clinical studies, with the fourth-generation HIV test "designed to detect both HIV-1/2 antibodies and the HIV-1 p24 antigen".

The company said the addition of p24 antigen detection would "enable earlier identification of infections compared with antibody-only third-generation tests, depending on the test's performance, specimen type and stage of infection".

Atomo said the rapid test would "use lateral-flow technology to detect these biomarkers in a blood sample, delivering results at the point of care without conventional laboratory equipment".

The company said within four months, the parties would agree to negotiate licence, development and supply agreements, with Atomo to commercialize the assay.

Atomo said it would be the manufacturer of the assay and planned to register the product with the Australian Therapeutic Goods Administration within 18 months.

The company said it expected to sign a supply agreement with Innovation Scientific to use its Galileo sub-assemblies in Innovation Scientific's test strip and buffer, delivering a final packaged product, and it expected to begin product commercialization within 24 months.

Atomo chief executive officer Cheri Walker said the partnership allowed the company "to rapidly complete the development and studies necessary to pursue the appropriate regulatory filings required for commercial launch of the product".

"We expect the commercial launch of both Gen 4 and Active Syphilis products within the next 24 months, establishing new revenue streams and supporting Atomo's next phase of growth," Ms Walker said.

Atomo fell 0.1 cents or 6.25 percent to 1.5 cents with 4.6 million shares traded.

CERETAS

Ceretas says it has enrolled the first of 66 patients in its phase II trial of therapeutic ultrasound for reducing Alzheimer's disease behavioral and psychological symptoms.

Last year, Ceretas said it raised $1 million in seed funding to develop its ultrasound therapy for neurological illnesses such as Alzheimer's disease (BD: Feb 21, 2025).

The company conducted an $8 million initial public offer at 25 cents a share for its portable ultrasound Alzheimer's disease therapy (BD: Aug 3, 2026).

Today, Ceretas said the first patient in the randomized, double-blind, sham-controlled, phase II trial was enrolled at Sydney's Cognivus Research, with additional sites at Sydney's St Vincent's Hospital and John Hunter Medical Institute.

The company said it expected the trial to be completed by July 2028.

Ceretas managing-director Dr Rachel de las Heras said the "enrolment of our first patient … represents an important milestone for Ceretas as we advance our therapeutic ultrasound technology through clinical development".

"Behavioral and psychological symptoms are among the most challenging aspects of Alzheimer's disease, placing a considerable burden on patients, families and healthcare systems," Dr de las Heras said.

"Our earlier phase I study provided encouraging evidence of safety and tolerability, together with early signals of clinical benefit," Dr de las Heras said.

"With recruitment now underway and additional clinical sites preparing to commence, our focus is on progressing patient enrolment and executing the study efficiently," she said.

Ceretas was up half a cent or 0.6 percent to 90 cents.

TETRATHERIX

Tetratherix says a 10-week, study shows its Tegeneos gel with platelet-rich plasma led to “significantly better” tendon and ligament injury healing, in rats.
Tetratherix said its Tegeneos bone graft carrier was a sterile, ready-to-use liquid in a syringe that was mixed with a patient’s platelet-rich plasma while cool, injected and set by the patient’s body heat into a cohesive gel; formulated using its Tetramatrix technology.
The company said the gel held the plasma at the injury site without letting it disperse and released the plasma proteins over a longer period than platelet-rich plasma alone, in laboratory testing.
Tetratherix said the study assessed Tegeneos in patellar tendon defects, below the kneecap, and found that untreated injuries still showed a gap at six weeks and traces of old bleeding at 10 weeks, confirming the injury did not heal on its own.
The company said platelet-rich plasma alone “produced a broad band of inflamed, scar-like tissue at the repair”.
Tetratherix said Tenegos with platelet-rich plasma showed “the repair at six weeks was crossed by organized new blood vessels, with less inflammation” and at 10 weeks was the “narrowest and most regularly aligned of the groups examined, and the blood vessels were still present”.
The company said the results showed the “tissue was rebuilding rather than scarring” and no section containing Tegeneos, with or without platelet-rich plasma, showed the features of a foreign body reaction at either time point.
Tetratherix did not disclose the type of animal used in the study but said it was preparing a study in horses to confirm the results in a larger animal model.
The company said Tegeneos continued to progress toward its US Food and Drug Administration 510(k) approval as a bone graft carrier, and platelet-rich plasma delivery added “a second application for the same product”.
Tetratherix founder and chief technology officer Dr Ali Fathi said it was “the same Tetramatrix chemistry that carries bone graft in Tegeneos, doing a second job … [turning] a bone graft carrier into a delivery platform for biologics, and it is a conversation we can now take to orthopaedic partners with data in hand”.
Tetratherix fell 15 cents or 2.7 percent to $5.35.

CONTROL BIONICS

Control Bionics says it has an unmarketable parcel facility for holders of shares worth less than $500, or 10,204 shares or fewer based on the closing price of 4.9 cents.
Control Bionics said there were 681 shareholders with unmarketable parcels, holding an aggregate 2,754,003 shares, at the record date of October 28, 2026.
The company said that GBA Capital was broker for shares sold under the facility.
Control Bionics was up 0.1 cents or 2.1 percent to 4.9 cents with 1.6 million shares traded.

PARADIGM BIOPHARMACEUTICALS

Paradigm administrator FTI Consulting says the Supreme Court of Western Australia has approved extending a second creditor meeting to January 27, 2027.
Last month, Paradigm appointed FTI Consulting as its administrator after it halted its 538-patient, phase III trial of pentosan polysulfate sodium, or Zilosul, for knee osteoarthritis, citing the data safety monitoring board finding that the interim efficacy result “did not reach the pre-specified threshold required for the study to continue” (BD: Sep 23, 30, 2026).
Paradigm was in administration and last traded at 24.5 cents.

ANTERIS TECHNOLOGIES GLOBAL CORP

Anteris says shareholders will vote on 24 resolutions, with 21 to grant 2,269,004 restricted stock units, 1,614,000 options and $1,600,000 in options to directors.
Anteris said its annual general meeting would vote to issue managing-director Wayne Paterson 1,429,921 restricted stock units and 1,200,000 options.
The company said investors would vote to issue chair John Seaberg $250,000 options to purchase either shares of common stock or Chess depository interests (CDIs) and up-to $540,000 worth of common stock in lieu of a portion of his cash retainer fees.
Anteris said it would vote to issue director David St Denis 799,960 restricted stock units and 414,000 options; and vote on the issue of 39,123 restricted stock units, $455,000 option rights and up-to $330,000 in shares in lieu of fees to director Susan Knight.
The company said invesors would vote to issue director Gregory Moss $455,000 option rights and up-to $330,000 worth of shares in lieu cash fees; as well as vote on the issue of $455,000 of options to director David Roberts and up-to $330,000 in lieu of his fees.
Anteris said the meeting would vote to issue company secretary and director Stephen Denaro $235,000 in options and $330,000 in CDIs in lieu of a portion of his fees.
The company said investors would vote on the election of Mr St Denis and Mr Denaro as directors, ratify the appointment of the auditor and approve the equity incentive plan.
The meeting will be held online and at the Intercontinental, 16 Phillip Street, Sydney on December 3, 2026 at 9am (AEDT).
Anteris was up 10 cents or 1.2 percent to $8.55.

NOXOPHARM

Noxopharm has requested a suspension following Tuesday's trading halt "pending an announcement … regarding a material capital raising" (BD: Oct 27, 2026).
Trading is expected to resume on November 2, 2026, or on an earlier announcement.
Noxopharm last traded at 5.2 cents.

NEURIZON THERAPEUTICS

Neurizon has requested a trading halt "pending an announcement by the company to the market regarding the outcome of a proposed capital raising".
Trading will resume on November 2, 2026, or on an earlier announcement.
Neurizon last traded at 8.6 cents.

RENERVE

Pogginswood Superannuation Fund says with Portia Finance Pty Ltd it has become a substantial shareholder in Renerve with 7,690,000 shares, or 5.48 percent.
Melbourne's Pogginswood and Portia Finance said that between June 22 and October 27, 2026 it bought shares at prices ranging from 7.4 cents to 9.26 cents a share.
Renerve was untraded at nine cents.